|
|||||
|
|
Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever |
|
| Authors: | D.-G. Lee MD,,H. Chae&dagger MD,,D.-S. Yim&dagger MD,,S. H. Park MD,,S.-M. Choi MD,,S. Kim MD,,J.-H. Choi MD,,J.-H. Yoo MD, W.-S. Shin MD |
| Affiliation: | Departments of Internal Medicine;and Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| Abstract: | Purpose: Empirical use of intravenous (IV) itraconazole (ITZ) for febrile neutropenic patients has recently been introduced in Korea. This study was designed to investigate the population pharmacokinetics (PK) of IV-ITZ. Methods: Sparse PK data were collected from febrile neutropenic patients undergoing empirical ITZ therapy at 200 mg/day after loading doses. NONMEM (Version. 5·1·1) was used to estimate population PK parameters. Results: Forty-two patients were enrolled in the study. Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively. Body weight was the only contributing covariate of CL. The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL. Conclusions: In this study, we explored the population PK profile of ITZ given in IV formulation. We found that the current dosage regimen of IV-ITZ (200 mg/day) was appropriate to obtain therapeutic trough concentrations for neutropenic patients in Korea. |
| Keywords: | itraconazole neutropenia NONMEM population pharmacokinetics |